#ESMOVirtualPlenary : A progression-free survival benefit was observed in women with germline BRCA1/2 mutations when treated with the #PARPi alone or in combination w/ apatinib.
Evandro de Azambuja, MD, PhD comments the results on the #ESMODailyReporter
👉dailyreporter.esmo.org/news/fuzulopar…
#mbc

Changing the treatment algorithm of Endometrial cancer...It is time for IO also in first-line!
Jaw-dropping results from ENGOT-EN6-NSGO/GOG-3031/RUBY #endometrialcancer #ESMOVirtualPlenary #gyncsm ESMO - Eur. Oncology AACR
ow.ly/p2pE50NsFAa

#ESMOVirtualPlenary : First analysis from IMADGIST shows #DFS benefit with 6yrs of maintenance therapy w/ imatinib compared to the 3yrs standard of care.

Read hans gelderblom perspective on these results on the #ESMODailyReporter
👉dailyreporter.esmo.org/news/prolonged…
#GIST

#ESMOVirtualPlenary : Tune in tomorrow (9/5) for the latest, promising findings for the treatment of metastatic #breastcancer (mBC). Open to everyone, everywhere. 📢 Fuzuloparib w/ or without apatinib in HER2- mBC pts w/ germline BRCA1/2 mutations: A randomised ph III trial.…

⏰ 27 Mar 2023 at 18:30 CEST
👀📢

Dostarlimab+chemotherapy for the treatment of primary advanced or recurrent (A/R) endometrial cancer (EC): A placebo (PBO)-controlled randomised phase III trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)

link: ➡️bit.ly/40rrFww

#ESMOVirtualPlenary

📣What a day! 💥 2 PIII trials:
RUBY trial ➡️ practice changing results in #endometrialcancer What a terrific #ESMOVirtualPlenary ✨
NATALEE trial ➡️ met the primary EP of iDFS in #breastcancer in #pressrelease Waiting 4 results 🔜
ESMO - Eur. Oncology AACR #immunotherapy #precisiononcology

What an amazing ESMO Virtual Plenary! It has been such an honor to discuss the important and practice changing results of the RUBY trial with Mansoor Mirza AnaOaknin MD PhD and Elise Kohn #ESMOVirtualPlenary ESMO - Eur. Oncology AACR #endometrialcancer #immunotherapy

📣📣📣Amazing results of the addition of Dostarlimab to chemotherapy in first line endometrial cancer. 🔥for dMMR/MSI-H ESMO - Eur. Oncology #ESMOVirtualPlenary

annalsofoncology.org/article/S0923-…

#ESMOVirtualPlenary : And straight after the first abstract session tomorrow (9/5), remain connected to discover more promising results on #GIST . 📢 A randomised study of 6 vs 3 years of adjuvant imatinib in pts w/ localised GIST at high risk of relapse. ow.ly/rKAa50Rza70…

📣 Join this important #ESMOVirtualPlenary
📍Monday March 27 at 18:30 CEST
➡️ #endometrialcancer #Immunotherapy #chemotherapy

ESMO - Eur. Oncology Eager for the latest mBC treatment insights from #ESMOVirtualPlenary !

The recent #ESMOVirtualPlenary presented event-free survival & overall survival results from the RATIONALE-315 study in pts w/ resectable non-small cell #LungCancer . Access the on-demand resources to stay up to date w/ the latest data.
🔗ow.ly/fYWW50QFfwx
#NSCLC #LCSM AACR

Fuzuloparib ± Apatinib Significantly Boosts PFS in BRCA+ HER2– Metastatic Breast Cancer ESMO - Eur. Oncology #ESMOVirtualPlenary #bcsm #oncology
onclive.com/view/fuzulopar…

#ESMOVirtualPlenary : Does the addition of perioperative tislelizumab to neoadjuvant chemotherapy improve survival outcomes for patients with resectable #NSCLC ? ⏲️ Today (15/2) at 18:30 CET: 👉ow.ly/kVrX50QAxhZ
Marina Garassino Luis Paz-Ares Justin Gainor AACR

#ESMODailyReporter : Perioperative tislelizumab improves survival in resectable #NSCLC – a new standard of care? Encouraging EFS & OS results presented at today's #ESMOVirtualPlenary for the use of the immune checkpoint inhibitor before & after surgery.

ow.ly/iSRe50QC79s?

#ESMOVirtualPlenary : 📣 Don’t miss today’s ESMO Virtual Plenary Expert Insights session to stay up to date with the latest, original data in #LungCancer : ⏲️ Today (16/2) at 13:00 CET 👉ow.ly/kVrX50QAxhZ
Marina Garassino Luis Paz-Ares Justin Gainor AACR #LCSM

📢 Don’t miss today’s #ESMOVirtualPlenary Insights session to stay up to date with the latest, original data in #lungcancer ⏲️ Today (17/11) at 13:00 CET.
ow.ly/sbv850Q7Ozl

Byoung Chul Cho, M.D., Ph.D. Tetsuya Mitsudomi Sanjay Popat Hochmair Maximilian

#ESMOVirtualPlenary : Join us for the latest data in #LungCancer 👉 RATIONALE-315: EFS & OS of neoadjuvant tislelizumab (TIS) plus chemotherapy with adjuvant TIS in resectable #NSCLC .
⏲️ 15 & 16 Feb.
ow.ly/ikMQ50Qvlwj
Marina Garassino Luis Paz-Ares Justin Gainor AACR

#ESMOVirtualPlenary 📢 What is the recommended dosage of sotorasib for pretreated KRAS G12C #advancedNSCLC ?
Access w/ yr free ESMO account to find out & submit questions to experts.
⏲️ Today at 18:30 CET
ow.ly/sbv850Q7Ozl

Byoung Chul Cho, M.D., Ph.D. Tetsuya Mitsudomi Sanjay Popat Hochmair Maximilian

#ESMOVirtualPlenary 📢 Mark your calendar: connect to this live, online presentation of the latest research in #LungCancer . ⏲️ Tomorrow (16/11) at 18:30 CET.
ow.ly/sbv850Q7Ozl

Byoung Chul Cho, M.D., Ph.D. Tetsuya Mitsudomi Sanjay Popat Hochmair Maximilian #LCSM